3-5 April 2022 Manchester
![]() |
![]() |
![]() |
![]() |
PO-001 | Oral azacitidine in patients with acute myeloid leukemia in first remission after intensive chemotherapy: long-term overall survival results from the phase 3 QUAZAR AML-001 trial | Dale Owens | ![]() |
![]() |
|||
EP-001 | Next generation sequencing in myeloid neoplasms: the South East of Scotland Experience | Christopher Mullen | ![]() |
![]() |
|||
EP-002 | Are Individuals of a Lower Socio-Economic Class Not Able to Receive Treatment for Acute Myeloid Leukemia due to Cost? A Prospective Analysis of 200 Patients in India. | Sasmith Menakuru | ![]() |
![]() |
|||
EP-003 | The UK Real-world Experience of CPX-351 for the Treatment of Therapy-related Acute Myeloid Leukaemia and Acute Myeloid Leukaemia with Myelodysplasia-related Changes: CREST Retrospective Clinical Trial Design | Priyanka Mehta | ![]() |
![]() |
|||
PO-004 | Performances of Targeted RNA Sequencing for the Analysis of Fusion, Mutation, Exon Skipping and Expression in Hematological Tumors | Jing Li | ![]() |
![]() |
|||
EP-004 | Leukocytapheresis for hyperleukocytosis in acute myeloid leukaemia a survey of current practice | Julia Wolf | ![]() |
![]() |
|||
PO-005 | Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias | Rana Zeeshan Haider | ![]() |
![]() |
|||
EP-005 | Blinatumomab and inotuzumab ozogamicin for acute lymphoblastic leukaemia: data from the South East Scotland Cancer Network | Christopher Mullen | ![]() |
![]() |
|||
PO-006 | One size fits all: a fixed (not weight-adjusted) dose of prophylactic liposomal amphotericin B is not associated with a higher rate of breakthrough invasive fungal infections in patients with higher weight | Sion Williams | ![]() |
![]() |
|||
EP-006 | Fever-to-needle time in the neutropenic cohort: are we meeting the gold-standard? | Kritika Kalia | ![]() |
![]() |
|||
EP-007 | Single Center, Real-world Retrospective Analysis of the Use of Azacitadine and Venetoclax as First Line Treatment In Patients with Acute Myeloid Leukaemia During the COVID-19 Pandemic | Sarah Ahmed Bassiony | ![]() |
![]() |
|||
PO-007 | Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Therapy-related Myeloid Neoplasms, Antecedent Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | Kathryn Moulton | ![]() |
![]() |
|||
PO-008 | CPX-351 Treatment for Acute Myeloid Leukaemia in England: Real-world Outcomes in Adults Aged 60 Years | Alex Legg | ![]() |
![]() |
|||
EP-008 | A simple intervention improved compliance with the COVID-19 swabbing policy for patients receiving chemotherapy in the Royal Bolton Hospital haematology department | Lowri Edwards | ![]() |
![]() |
|||
EP-010 | Analysis of Haematology Consult Cases to Design a Consult Request Pro Forma in a Tertiary University Teaching Hospital | David Egong | ![]() |
![]() |
|||
PO-011 | Purified phospholipase A2 from Pseudechis australis snake venom a novel anticancer agent for the treatment of precursor-B acute lymphoblastic leukaemia. | James Boncan | ![]() |
![]() |
|||
PO-012 | Management of non-severe aplastic anemia: laboratory workup and treatment patterns. | Giulio Cassanello | ![]() |
![]() |
|||
EP-012 | Review of bone marrow aspiration and trephine biopsies; a single university hospital report | Zahraa Al-Dulaimi | ![]() |
![]() |
|||
EP-013 | Review of local practice and experience: a survey regarding bone marrow biopsies in a UK tertiary centre | Kiri Dixon | ![]() |
![]() |
|||
PO-013 | Reporting Language in Haematological Malignancies | Sophie Ralston | ![]() |
![]() |
|||
PO-014 | Audit outcomes of the Referral Pathway for Haematology Patients to the Intensive Care Facility at the University Hospital of Wales During the COVID Pandemic | Medhavi Ratnayake | ![]() |
![]() |
|||
EP-014 | Haematology SpR Patient Safety Lead: A valuable contribution to Clinical Governance | Michelle Melly | ![]() |
![]() |
|||
EP-015 | Thrombocytopenia in COVID-19 patients on ECMO | Can Jones | ![]() |
![]() |
|||
PO-015 | Choose your own story: combining interactive voting technology with high-fidelity patient simulation for undergraduate transfusion teaching | Sophie Holmes | ![]() |
![]() |
|||
EP-016 | Dasatinib Related Pleural Effusions: Real-World Experience in a District General Hospital | Wing Yee Chris Sin | ![]() |
![]() |
|||
PO-016 | Under or delayed transfusion: Risk factors leading to patient deaths. | Shruthi Narayan | ![]() |
![]() |
|||
PO-017 | Reducing Unnecessary Blood Tests on a Haematology Ward at Salisbury NHS Foundation Trust | Lee Grimes | ![]() |
![]() |
|||
EP-017 | Adherence to national guidelines for patients with very low B12 levels 15Ong/l | Wayne Thomas | ![]() |
![]() |
|||
PO-018 | A multidisciplinary approach to improvement of a bone marrow biopsy service: advice from both service users and service providers | Kiri Dixon | ![]() |
![]() |
|||
EP-018 | PERFORMANCE OF SOME HAEMATOLOGICAL MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PREECLAMPSIA | Theresa Nwagha | ![]() |
![]() |
|||
PO-019 | Home transfusions balancing safety with individualised care | Shruthi Narayan | ![]() |
![]() |
|||
EP-019 | Prevalence and clinicopathological features of driver mutations in BCR-ABL1 negative classical myeloproliferative neoplasm- A single centre study from North India | Khaliqur Rahman | ![]() |
![]() |
|||
EP-020 | IMMUNE THROMBOCYTOPENIA: BE ALWAYS AWARE | Paula Melero Valentín | ![]() |
![]() |
|||
PO-020 | Endocrine Complications in Patients with Thalassemia: A Single Centre Experience | Maab Ibrahim | ![]() |
![]() |
|||
PO-021 | The Haematology Taster Day Inspiring the next generation of haematologists | Julia Wolf | ![]() |
![]() |
|||
EP-021 | Platelets Indices as Diagnostic Markers for Immune Thrombocytopenia and Surrogate Predictors for Prednisolones Response, Khartoum - Sudan | Rabea Saeed | ![]() |
![]() |
|||
PO-022 | Strangers in a foreign land: Foundation year 1 doctors introduction and experiences in Haematology-Oncology | Alessandra Lepori | ![]() |
![]() |
|||
EP-022 | Effect of Iron Deficiency Anemia on HbA1c levels in a cohort of patients with Type 2 diabetes mellitus(T2DM) in Sri Lanka. | Chitranga Kariyawasan | ![]() |
![]() |
|||
PO-023 | Developing the role of the Haematology ward in undergraduate medical education with the creation of a novel clinical placement | Richard Hinton | ![]() |
![]() |
|||
EP-023 | Usefulness of Ferritin and sTfR/(log)ferritin (sTfR-F) index in identifying iron deficiency anaemia among blood donors | Theresa Nwagha | ![]() |
![]() |
|||
EP-024 | Reducing Platelet Wastage in a Regional Australian Haematology Centre: Impact of Phone Calls to Clinical Staff for Expiring Platelet Stock | Emily Powley | ![]() |
![]() |
|||
PO-024 | Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies | Cory Pfeiffenberger | ![]() |
![]() |
|||
EP-025 | Increasing incidence of Folate and Vitamin B12 deficiency in pregnant population and Risk Stratification of at risk women with early diagnosis and management | Rakhee Saxena | ![]() |
![]() |
|||
PO-025 | Treatment free responses and long term outcomes in ITP patients with an optimal response to thrombopoietin receptor agonists | Asad Charania | ![]() |
![]() |
|||
EP-026 | Evaluation of the hematological changes in the full blood count of regular apheresis platelet donors at National Blood Centre Narahenpita in Sri Lanka. | Gauri Jayasinghe | ![]() |
![]() |
|||
PO-026 | Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib | Gemma Shay-Lowell | ![]() |
![]() |
|||
PO-027 | Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis update of clinical and translational data from the ongoing MANIFEST trial | Hannah Greetham | ![]() |
![]() |
|||
EP-027 | Assessment of the Relationship between ferritin levels and hematological ratios in Thalassemia Major | Dorra Rhim | ![]() |
![]() |
|||
PO-028 | EMT transcription factor Zeb1 regulates T-cell differentiation from haematopoietic stem cells during ontogenesis | Hamed Alzahrani | ![]() |
![]() |
|||
EP-028 | Adapting heparin monitoring in response to COVID-19 | Emily Patrick | ![]() |
![]() |
|||
EP-029 | Impact Of National Hemovigilance Reporting System: A Report From Private Hospital Based Blood Centre In India. | Bala Bhasker | ![]() |
![]() |
|||
PO-029 | Association of red blood cell distribution width and lactate dehydrogenase with disease transformation in essential thrombocythaemia and polycythaemia vera patients: a UK cohort study using electronic health records | Lewis Carpenter | ![]() |
![]() |
|||
EP-030 | massive transfusion or massive confusion? | Mariem Cheikhrouhou | ![]() |
![]() |
|||
PO-031 | Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib | Ruben Mesa | ![]() |
![]() |
|||
EP-031 | Consequences of immune defects in patients with diffuse large B cell lymphoma (DLBCL). | Katarina Flatman | ![]() |
![]() |
|||
PO-032 | Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Nave Myelofibrosis Patients | Ruben Mesa | ![]() |
![]() |
|||
EP-032 | Relapsed/Refractory Hodgkins lymphoma: a real world analysis of salvage therapy in the East of England | Patrick Sarkies | ![]() |
![]() |
|||
EP-033 | Venous thromboembolism in newly diagnosed lymphoma patients: A review of 102 patients in a district general hospital aiming to identify those at risk | Aoife Dervin | ![]() |
![]() |
|||
PO-033 | Effects of cessation of venesection on serum ferritin level and liver function among older patients with haemochromatosis as a result of the Covid-19 pandemic. | Omolade Dada | ![]() |
![]() |
|||
PO-034 | Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic Jaki Nave Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status | Jean-Jacques Kiladjian | ![]() |
![]() |
|||
EP-034 | Osteoporotic fracture risk in Non-Hodgkins lymphoma patients over the age of 70 treated with glucocorticoid containing chemo-immunotherapy regimens; A retrospective audit at a District General Hospital | Patrick Isola | ![]() |
![]() |
|||
PO-035 | Characterisation of Cardiovascular Risk in a Contemporary Cohort of Patients with Myeloproliferative Neoplasms | Dipal Mehta | ![]() |
![]() |
|||
EP-035 | Experience of delivering MATRIX chemotherapy and autologous stem cell transplant for central nervous system lymphoma within South East Scotland | Sarah Beverstock | ![]() |
![]() |
|||
PO-036 | Pegylated Interferon is an effective and well-tolerated cytroreductive agent in patients with myeloproliferative neoplasms aged over 60 years. | Hannah Al-Yousuf | ![]() |
![]() |
|||
EP-036 | Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial | Lay Ean Tan | ![]() |
![]() |
|||
PO-037 | Iron Status of Pregnant Women with Sickle Cell Disease (SCD) | Edeghonghon Olayemi | ![]() |
![]() |
|||
EP-037 | Course features and the effect of various therapies on the treatment outcome of hepatitis C associated marginal zone lymphoma (HCVMLZ) | Sergey Lepkov | ![]() |
![]() |
|||
PO-038 | Enhancing chronic myeloid leukaemia (CML) patient safety and treatment management - Development of a management and audit tool for patients on tyrosine kinase inhibitor (TKI) therapy. | Toby Jones | ![]() |
![]() |
|||
EP-038 | Ibrutinib therapy related uveitis: A single-centre case series and literature review | Anita J M Kalakonda | ![]() |
![]() |
|||
EP-039 | Management of Primary Testicular Lymphoma within South-East Scotland within the last 10 years | Jennifer Clarke | ![]() |
![]() |
|||
PO-039 | Assessing the utility of peripheral blood monocyte analysis and the fraction of classical monocytes (CD14ve CD16-ve) in the diagnosis of Chronic Myelomonocytic Leukaemia. | Jennifer Mills | ![]() |
![]() |
|||
EP-040 | A Retrospective Analysis of the Covid-19 Pandemic Effect on Lymphoma Presentations and Diagnostic Pathways at Salisbury NHS Foundation Trust | Lee Grimes | ![]() |
![]() |
|||
PO-040 | Sickle screening of Blood Donors in Scotland using High Performance Liquid Chromatography. Are we opening Pandoras box? | Nicole Priddee | ![]() |
![]() |
|||
EP-041 | Quality of Life Reported Outcomes in Published Research on Waldenstroms Macroglobulinaemia: A systematic literature review | Sotirios Bristogiannis | ![]() |
![]() |
|||
PO-042 | An audit of compliance with BSH haemoglobinopathy patients transfusion requirements and antibody prevalence in UK tertiary centre hospital blood bank. | Suzanne Makki | ![]() |
![]() |
|||
EP-043 | Impact of CD38 Gene Polymorphism (rs1800561) on Hematological Parameters and Clinical Staging in Patients with Chronic Lymphocytic Leukemia | Sahar Elbager | ![]() |
![]() |
|||
PO-043 | Time to first plasma exchange in TTP - a regional Scottish experience | Christopher Mullen | ![]() |
![]() |
|||
EP-044 | Results of the treatment of patients with local stages of Hodgkins lymphoma | Evgeniya Paramonova | ![]() |
![]() |
|||
PO-045 | Assessment of intoxication indexes in local cold injury | Gennadiy Kovalov | ![]() |
![]() |
|||
PO-046 | Improving compliance with blood and platelet transfusion thresholds on a tertiary haematology ward | Jenny Jia Ling Cao | ![]() |
![]() |
|||
EP-046 | Outcomes of patients referred with lymphadenopathy to the haematology service in the London North West University Healthcare NHS Trust between January 2019 and March 2021 | Clemency Britton | ![]() |
![]() |
|||
EP-047 | Comparing the Psychosocial Impacts of the COVID-19 Pandemic Between Haematological Cancer and Myeloma Patients: Findings From an Online Survey | Stephen Quinn | ![]() |
![]() |
|||
PO-047 | HIV, Hepatitis B and C viruses and syphilis coinfection among blood donors inhospital settings. | Supriya Kumari | ![]() |
![]() |
|||
PO-048 | Haematological changes & in-hospital mortality in severe COVID-19 | Sergio Gama | ![]() |
![]() |
|||
EP-048 | Quality of life assessment in multiple myeloma is feasible, biologically meaningful and can suggest appropriate interventions. | Luke Carter-Brzezinski | ![]() |
![]() |
|||
PO-049 | ABO-related D-dimer elevation and severity In SARS-cov2-infected Tunisian patients | Amira Hourani | ![]() |
![]() |
|||
EP-049 | Real-world experience of thrombotic complications associated with immunomodulatory (IMID) therapy in newly diagnosed and relapsed patients with multiple myeloma (MM). | Lowri Morgan | ![]() |
![]() |
|||
EP-050 | Carfilzomib-related thrombotic microangiopathy a single centre case series | Muhammed Saleh | ![]() |
![]() |
|||
PO-050 | RDW: useful prognostic marker in acute COVID-19 infection | Sergio Gama | ![]() |
![]() |
|||
EP-051 | Survival in multiple myeloma patients following autologous stem cell transplantation, a single centre retrospective case series between 2015 and 2020 | Rufaida Osman | ![]() |
![]() |
|||
EP-052 | Clinical utility of investigating for immune deficiency disease and light chain myeloma at low globulin levels | indra ramasamy | ![]() |
![]() |
|||
EP-053 | Pegcetacoplan Patient Compliance Rates In PEGASUS And PRINCE Phase 3 Trials Compared To Published Oral Medication Compliance Rates In Literature | Michael Yeh | ![]() |
![]() |
|||
PO-053 | Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results | Carmen Ramirez | ![]() |
![]() |
|||
EP-054 | The uptake of vaccinations in adults with sickle cell disease receiving care at the Cambridge University Hospitals NHS Foundation Trust | Joanna Kucharczak | ![]() |
![]() |
|||
EP-055 | Right dose, right time and right communication: patient feedback on management of acute painful episodes of sickle cell disease | Sophie Holmes | ![]() |
![]() |
|||
PO-055 | Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study | Sukanya Chaudhury | ![]() |
![]() |
|||
PO-056 | Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study | Sukanya Chaudhury | ![]() |
![]() |
|||
EP-056 | Thromboprophylaxis for Nursing home residents with COVID-19 a single centre approach | Radha Shah | ![]() |
![]() |
|||
PO-057 | Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Jacqueline Webster | ![]() |
![]() |
|||
EP-057 | Pattern of Venous Thrombosis events in 2020 associated with COVID, in a large teaching hospital | Huw Rowswell | ![]() |
![]() |
|||
PO-058 | Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study | Will Cherry | ![]() |
![]() |
|||
EP-058 | ASSOCIATION OF MEAN PLATELET VOLUME / PLATELET COUNT RATIO WITH CLINICAL SEVERITY AND INFARCT VOLUME IN PATIENTS WITH ACUTE ISHEMIC STROKE | Muhammad Wasi Nayyar | ![]() |
![]() |
|||
PO-059 | Real-World Experience of Rapid Obinutuzumab Administration: Time to Change Obinutuzumab Infusion Rates | Joel Cunningham | ![]() |
![]() |
|||
EP-059 | A single centre retrospective review looking at antiphospholipid screens for those on DOACs including follow up testing and the subsequent clinical sequelae. | Michelle Melly | ![]() |
![]() |
|||
EP-060 | Increased levels of factor VIII on admission, predict intensive care unit transferal and mortality in hospitalized COVID-19 patients. | Mohamed El Horri | ![]() |
![]() |
|||
PO-060 | Outcomes and prognostic factors for adult patients with Post-Transplant Lymphoproliferative Disorders: the Thames Valley experience | Maria Chiara Barbanti | ![]() |
![]() |
|||
PO-061 | The MCL Biobank Observational Study comes of age | Sarah Mant | ![]() |
![]() |
|||
EP-061 | Collaborative anticoagulation counselling for recently discharged patients: From hospital to the community pharmacy | Abigail Mezzullo | ![]() |
![]() |
|||
EP-062 | Subcutaneous unfractionated heparin in patients with end stage kidney disease requiring anticoagulation | Giulia Simini | ![]() |
![]() |
|||
PO-062 | BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress) | Sukanya Chaudhury | ![]() |
![]() |
|||
PO-063 | Bisphosphonate prophylaxis in Lymphoma patients treated with steroid containing regimens | Rashmi Chandrashekar | ![]() |
![]() |
|||
EP-063 | Improving venous thromboembolism risk assessment practice and prophylaxis prescription for the patients admitted to medical assessment unit | Amar Ali | ![]() |
![]() |
|||
EP-064 | Case series of the first use of Andexanet Alfa at Salisbury NHS Foundation Trust | Lee Grimes | ![]() |
![]() |
|||
PO-064 | Efficacy of Mogamulizumab in Mycosis Fungoides by Patient Blood Involvement and Time to Response Analysis in Mycosis Fungoides and Sézary Syndrome: a Post Hoc Analysis of the MAVORIC Study | Lay Ean Tan | ![]() |
![]() |
|||
EP-065 | A retrospective review of the role of platelet aggregometry in the diagnosis of platelet disorders in a single Comprehensive care centre | Benjamin Gray | ![]() |
![]() |
|||
PO-065 | Undiagnosed Lymphadenopathy Pathway Is a Haematology-led service warranted? | Rachel Wright | ![]() |
![]() |
|||
PO-066 | Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy; a Single Centre Study | John Hall | ![]() |
![]() |
|||
PO-067 | Real-World Outcomes for Dexamethasone, Rituximab and Cyclophosphamide (DRC) in the Treatment of Waldenström Macroglobulinaemia: An Eight-Year Retrospective Review | Ravindu De Silva | ![]() |
![]() |
|||
EP-067 | An audit of therapeutic anticoagulation with Anti-Xa monitoring during pregnancy | Sajida Kazi | ![]() |
![]() |
|||
PO-068 | Identification of a Novel Proliferating Cell Fraction in Chronic Lymphocytic Leukaemia with High Expression of IgM and Chemokine Receptors | Robbert Hoogeboom | ![]() |
![]() |
|||
EP-068 | ALLELE Study: A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV PTLD) after Failure of Rituximab | Sridhar Chaganti | ![]() |
![]() |
|||
PO-069 | A novel cardio-oncology pathway for the detection of early toxicity in patients receiving anthracycline chemotherapy for lymphoma | Clare Bannister | ![]() |
![]() |
|||
EP-070 | Is Posaconazole Therapeutic Drug Monitoring Required In Primary Prophylaxis Of Invasive Fungal Disease In Adult Allogeneic Stem Cell Recipients? | David Quinn | ![]() |
![]() |
|||
PO-070 | BRUIN MCL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Nave Mantle Cell Lymphoma (Trial in Progress) | Sukanya Chaudhury | ![]() |
![]() |
|||
PO-071 | CARTITUDE-2 Cohort B: Efficacy and Safety of Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T-Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients With Multiple Myeloma and Early Relapse After Initial Treatment | Priyanka Nair | ![]() |
![]() |
|||
EP-071 | Reduced intensity conditioning with fludarabine,treosulfan and anti-thymocyte globulin (FluTreoATG) - A single centre experience | Yadanar Lwin | ![]() |
![]() |
|||
EP-072 | Pregnancy outcomes following bone marrow transplant: findings of clinician survey and update on data linkage and UKOSS survey | Katherine Birchenall | ![]() |
![]() |
|||
PO-072 | First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma | Jared Saunders | ![]() |
![]() |
|||
EP-073 | A real-world evidence systematic literature review of the metrics used to detect veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation | Diane Lockard | ![]() |
![]() |
|||
EP-074 | The emerging advanced nurse practitioner role in haematology-does it cause confusion or provide support to the traditional clinical nurse specialist role? | Roxanne Spencer | ![]() |
![]() |
|||
EP-075 | Nurse-led Telephone Clinics for Myeloproliferative Neoplasms (MPN): Developing service provision through COVID-19 | Hayley Gleadhill | ![]() |
![]() |
|||
PO-075 | Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multipl | Salgo Elenjikamalil | ![]() |
![]() |
|||
EP-076 | Role of IL6 in developing resistance of AML cells to standard chemotherapy | Ahmed Elmarghany | ![]() |
![]() |
|||
PO-076 | The impact of a delayed diagnosis on myeloma patients quality of life | Amy Capper | ![]() |
![]() |
|||
PO-077 | Treatment delivery and outcomes in elderly myeloma patients at The Royal Bournemouth hospital; Real life data | Alistair Smith | ![]() |
![]() |
|||
EP-077 | Pattern of Haemolysis During Pregnancy in Women with Sickle Cell Disease (SCD), and its Effects on Feto-maternal Outcome | Edeghonghon Olayemi | ![]() |
![]() |
|||
EP-078 | Real World Data on Efficacy of Pharmaceutical-grade L-glutamine in preventing Sickle Cell Disease-related acute complications and haemolysis in Pediatric and Adult patients. | Mohamed Yassin | ![]() |
![]() |
|||
PO-079 | Haematology clinic presentation of benign plasma cell granuloma and lymphomatoid granulomatosis with intracranial involvement - a case series. | Kanchana De Abrew | ![]() |
![]() |
|||
EP-079 | An Audit Of The Process Of Care In Surveillance Services For Children With Sickle Cell Disease In Wales | Charlie Jeffkins | ![]() |
![]() |
|||
EP-080 | Prevalence of Bleeding Disorders in Nicaragua in the period 2004-2020. | Sergio Luis Gustavo Aguilera Covarrubias | ![]() |
![]() |
|||
EP-081 | Beginning of the Hemophilic Arthropathy in children of 7 to 11 years old in Nicaragua in the absence of replacement treatment: Series of 9 cases. | Sergio Luis Gustavo Aguilera Covarrubias | ![]() |
![]() |
|||
PO-081 | Outcomes of Patients (pts) with Previously Treated Multiple Myeloma (MM) from European Countries and the United Kingdom, Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd): A Post-Hoc Analysis from the BOS | Tamar Aprahamian | ![]() |
![]() |
|||
PO-082 | A META-ANALYSIS OF THE RATE OF MALIGNANT PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: PRELIMINARY FINDINGS FROM A SYSTEMATIC REVIEW | Stephen Quinn | ![]() |
![]() |
|||
PO-083 | Are we looking for Monoclonal Gammopathy of Renal Significance (MGRS)? An audit of investigations in current clinical practice | Lisa Jeffers | ![]() |
![]() |
|||
PO-084 | Quality of Life and Symptom Burden of Paroxysmal Nocturnal HaemogIobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe | Shaneil Sonecha | ![]() |
![]() |
|||
PO-085 | Retrospective analysis of the burden of vasoocclusive events experienced by sickle cell disease (SCD) patients in the integrated health and social care system in North West London | Amir Nawaz | ![]() |
![]() |
|||
PO-086 | The Pharmacokinetics, Pharmacodynamics, And Safety Of Intravenous Pegcetacoplan Administration In Healthy Subjects | Michael Yeh | ![]() |
![]() |
|||
PO-087 | Association of CR1 and C3 polymorphisms with C3-mediated extravascular haemolysis in Paroxysmal Nocturnal Haemoglobinuria | April Joy Baral | ![]() |
![]() |
|||
PO-089 | Real-World Experience of Patients With Sickle Cell Disease Treated With Voxelotor: A Multicenter, Retrospective Study | Biree Andemariam | ![]() |
![]() |
|||
PO-090 | Pegcetacoplan Treatment In Patients With Paroxysmal Nocturnal Hemoglobinuria And Baseline Hemoglobin Levels At Or Above 10 g/dL | Michael Yeh | ![]() |
![]() |
|||
PO-091 | Predictors for improvement in patient-reported outcomes: post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-nave patients with paroxysmal nocturnal hemoglobinuria (PNH) | Colin Griffin | ![]() |
![]() |
|||
PO-094 | Breakthrough Hemolysis Rates Among Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switched From Eculizumab to Ravulizumab Treatment: A Real-World Analysis | Michael Yeh | ![]() |
![]() |
|||
PO-095 | Management of autoimmune haemolytic anaemia during pregnancy or post-partum: a single centre experience. | Marta Bortolotti | ![]() |
![]() |
|||
PO-096 | Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation From International PNH Registry Patient Data | Colin Griffin | ![]() |
![]() |
|||
PO-098 | Mapping the Prothrombin Binding Site of Pseutarin C by Site-directed PEGylation | Fatma Isik Ustok | ![]() |
![]() |
|||
PO-099 | Efficacy of thrombopoietin receptor agonists in Evans syndrome: an international multicenter experience | Nicola Cecchi | ![]() |
![]() |
|||
PO-101 | Postdischarge complications and mortality of hospitalised patients with COVID-19 in East London Hospitals | Aiman Entwistle | ![]() |
![]() |
|||
PO-102 | Drug-induced thrombotic thrombocytopenic purpura (TTP): review of European and North American pharmacovigilance report data | Sara Hosseinzadeh | ![]() |
![]() |
|||
PO-103 | Safety and Efficacy of Apixaban as Thromboprophylaxis in Multiple Myeloma Patients Receiving Chemotherapy: a Prospective Cohort Study | Zara Sayar | ![]() |
![]() |
|||
PO-105 | Platelet function abnormalities are common amongst women with menorrhagia referred for surgical intervention | Alison Delaney | ![]() |
![]() |
|||
PO-107 | The advantages of using expansion microscopy to visualise single platelets and aggregates | Raluca Alexandra Iulia Neagoe | ![]() |
![]() |
|||
PO-108 | Tranexamic Acid use to improve outcomes in Meningioma Surgery | Abigail Clynch | ![]() |
![]() |
|||
PO-109 | Internal and external validation of venous thromboembolism predictive model in hematologic malignancies. | Agnerys López Sacerio | ![]() |
![]() |
|||
PO-110 | Thromboembolism in COVID-19 patients on ECMO | Can Jones | ![]() |
![]() |
|||
PO-111 | Vaccine Induced Immune Thrombocytopenia and Thrombosis Syndrome post second dose of ChAdOx1 nCov-19 vaccine: Case Presentation | Amy Webster | ![]() |
![]() |
|||
PO-113 | The effect of lockdown and media coverage following vaccine rollout on Deep Vein Thrombosis (DVT) clinic activity during the first year of the COVID-19 pandemic a single-centre experience. | George Bell | ![]() |
![]() |
|||
PO-114 | Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma | Patrick Deifik | ![]() |
![]() |
|||
PO-115 | Excellent outcome with FB4 conditioning regimen in patients affected with myeloid malignancies older than 55 and with HCTI-score 2. A new insight for raising the upper limit for myeloablation in fit patients and high-risk diseases. | Daniele Avenoso | ![]() |
![]() |
|||
PO-116 | Use of a foamy-virus vector system to produce an off-the-shelf anti-CD19 CAR T cell product | Ioanna Lazana | ![]() |
![]() |
|||
PO-118 | The future of Outpatient Haematology : Self Supported Follow-up (SSFU) for patients with Chronic Lymphocytic Leukaemia (CLL) and Monoclonal Gammopathy of Undetermined Significance (MGUS) - An online Portal audit. | Ruth Jackson | ![]() |
![]() |
|||
PO-121 | Just one thing what would myeloma patients change about their treatment and care? | Jess Turner | ![]() |
![]() |
|||
PO-122 | Disease Knowledge in Adolescents and Young Adults with Sickle Cell Disease in a Low Resource Setting. | Bonaventure Ikediashi | ![]() |
![]() |
|||
PO-123 | What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis? | Nick Fordham | ![]() |
![]() |
|||
PO-124 | Aberrant expression of lncRNA leukemia-induced non-coding activator RNA predicts poor Outcome in Childhood T-Acute Lymphoblastic Leukemia | Nashwa El-Khazragy | ![]() |
![]() |
|||
PO-125 | National protocol required for consistent transfusion duration in patients having regular tranfusion ? Resulrs from a national survey and recommendations | Eleni Louka | ![]() |
![]() |
|||
PO-126 | Need to contextualize the fight against sickle cell disease in regions with limited resources: the case of the Democratic Republic of the Congo | Abdala Aimé | ![]() |
![]() |
|||
PO-127 | APPRAISAL OF QUALITY OF LIFE AND ASSESMENT OF FACTORS INFLENCING QUALITY OF LIFE IN TRANSFUSION DEPENDENT BETA THALESEMMIA - A CROSS SECTIONAL STUDY | Srividhya Senthil | ![]() |
![]() |
|||
PO-128 | Individualized prophylaxis with personalized target trough FVIII level optimized clinical outcomes in boys with severe hemophilia A | Kun Huang | ![]() |
![]() |
|||
PO-129 | Thrombopoietin receptor agonists for treatment of new and relapsed immune thrombocytopenia in children- a single centre experience | Eman Hassan | ![]() |
![]() |
|||
PO-130 | DVT prophylaxis in sixteen and seventeen-year-olds and the NICE guidelines should adult risk assessment tools be used for children? | Jan Muhammad | ![]() |
![]() |
|||
PO-131 | A year of coagulation studies in a Paediatric Emergency Department: A service evaluation project | John Wilson | ![]() |
![]() |
|||
PO-132 | Positive Impact of Covid-19 on Providing Health Care Services: Experience from a Large Haemophilia Comprehensive Care Centre | Emma Whiting | ![]() |
![]() |
|||
PO-133 | Single Centre Study on Safety and Efficacy of Rivaroxaban in Paediatric Venous Thromboembolism | Eman Hassan | ![]() |
![]() |
|||
PO-134 | Impact of levofloxacin-based prophylaxis during the pre-engraftment phase in allogeneic hematopoietic stem cell transplant pediatric recipients: a single-center retrospective matched analysis. | Martina DAgostin | ![]() |
![]() |
3-5 April 2022 Manchester
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|